Effective preclinical assessment of drug safety and efficacy is essential to help reduce the risk of drug-induced toxicity and late-stage drug attrition. Current preclinical tests for safety depend on in vivo testing in higher-order species to achieve translational accuracy; however, animal models are expensive and do not adequately recapitulate human physiology due to species differences.
This webinar, hosted by DDW and supported by PerkinElmer, took place on 26 May.
Dr. Seyoum Ayehunie, Vice President, Scientific Research and Development, MatTek Corporation, will discuss the functionality and limitations of a novel in vitro 3D primary human cell-based tissue model for drug toxicity and efficacy studies.
Dr. Ayehunie’s talk will be followed by a presentation from Dr. Hyelim Cho, Group Lead, Immunogenicity, Global DMPK Oncology and Rare Diseases, Takeda Pharmaceuticals, who will explain why developing a predictive pre-clinical assay is key to success in immuno-oncology drug development.
What you will learn:
- How to evaluate models to establish robust and reliable preclinical investigation of drug candidates prior to entering clinical trials
- How to gain an understanding of the advancements in preclinical model systems and assays
- What to consider from the latest innovations and impact on bioanalytical assays
Who should attend:
- Preclinical development scientists
- Pharmacologists
- Toxicologists
- Bioanalytical assay development scientists
Watch on demand for free here
